Veradermics Reports Positive Phase 3 Results for Experimental Oral Hair-Loss Drug

Veradermics' Oral Minoxidil Pill Clears Phase 3 Hurdle in Male Pattern Hair Loss

Study 304 met its hair-count and patient-reported endpoints against placebo. Approval, long-term safety, and a launch date remain open questions.

Veradermics has reported positive topline results from a Phase 3 trial of VDPHL01, an experimental extended-release oral minoxidil being developed for male pattern hair loss. The company said Study 304 met all primary and secondary endpoints. The candidate has not been approved by the US Food and Drug Administration.

The results, announced October 19, 2026, add to evidence from the company's late-stage programme. They do not, on their own, establish that the drug is safe and effective for regulatory purposes — that assessment belongs to the FDA once a complete application is submitted.

Pattern hair loss, or androgenetic alopecia, is the most common form of hair loss in men. Existing prescription options include topical minoxidil and oral finasteride, which works through a hormone-related mechanism. VDPHL01 is being positioned as a potential oral, non-hormonal alternative.

What Study 304 measured

The six-month trial enrolled 536 men with mild-to-moderate pattern hair loss and compared two dosing schedules of VDPHL01 against placebo: 8.5 mg once daily and 8.5 mg twice daily.

After six months, the once-daily group recorded an average increase of 28.6 non-vellus hairs per square centimetre in the target scalp area. The twice-daily group recorded an increase of 36.4 hairs per square centimetre, compared with 6.6 in the placebo group — a difference of roughly 22 and 30 hairs per square centimetre, respectively, over placebo.

Non-vellus hair counts measure hairs more developed than fine, lightly pigmented vellus hairs. Researchers use the metric to assess change in hair growth within a defined scalp area.

The company said both active-treatment groups performed significantly better than placebo on the hair-count endpoint, with p-values below 0.0001. Study 304 also met its co-primary patient-reported outcome, which asked whether participants considered their hair coverage improved or much improved.

At six months, 55.7% of participants receiving once-daily VDPHL01 reported improved or much-improved coverage. That rose to 68.7% among those taking the drug twice daily, compared with 15.0% on placebo.

A broader measure that included any reported improvement showed 78.8% of the once-daily group and 85.0% of the twice-daily group reporting better coverage, compared with 35.3% on placebo. These are distinct outcome measures and should not be combined: reporting any improvement is not the same as reporting that coverage is improved or much improved.

Veradermics also said statistically significant separation from placebo appeared at Month 2, the earliest time point evaluated. That is a trial finding, not a clinical promise — it does not mean every patient should expect visible regrowth within two months.

Why extended release matters

Minoxidil is already used in hair-loss treatment, most commonly as a topical product applied to the scalp. Oral minoxidil tablets are FDA-approved in the United States for certain cases of severe hypertension, not for pattern hair loss. Some clinicians prescribe oral minoxidil off-label for hair loss, but off-label use is not the same as having an FDA-approved oral product for the indication.

VDPHL01 is designed to deliver minoxidil through an extended-release tablet. According to Veradermics, the formulation uses a gel matrix intended to release the drug over a longer period and avoid the high peak concentrations associated with immediate-release oral minoxidil.

The strategy aims to preserve the potential hair-growth effect while improving the product's safety and tolerability profile. The Phase 3 results are relevant to that goal, but they do not by themselves demonstrate that the extended-release formulation eliminates the cardiovascular risks associated with oral minoxidil. Answering that question requires the full clinical evidence and, if an application is submitted, regulatory review.

Safety findings: reassuring, not conclusive

Veradermics described VDPHL01 as generally well tolerated through six months. In Study 304, the company reported no treatment-related serious adverse events and no adverse events of special interest of cardiac origin. According to the trial presentation, there were no clinically significant differences in heart rate, blood pressure, or electrocardiogram changes compared with placebo.

Those findings are reassuring within the limits of the study. They should not be read as proof that the medicine carries no cardiac risk: the reported follow-up was six months, and the trial was not designed to rule out every uncommon or longer-term adverse event.

The company's safety table also recorded peripheral oedema — swelling caused by fluid accumulation — in 2.8% of participants on the once-daily dose and 4.5% on the twice-daily dose, compared with 0.6% on placebo. Hypertrichosis, or unwanted hair growth, occurred in 2.2% of the once-daily group and 9.0% of the twice-daily group; no placebo participants experienced it in Study 304.

Those figures matter because a treatment's practical value depends not only on whether it promotes hair growth but on the side effects patients experience, how manageable those effects are, and whether people continue taking the medicine. The twice-daily group produced the larger average hair-count increase, but it also had the higher reported rate of hypertrichosis. Patients and clinicians would need to weigh efficacy, safety, dosing, and individual circumstances if the product reaches the market.

A second registration-directed study

Study 304 is part of Veradermics' registration-directed programme. The company previously reported positive topline results from Study 302, a Phase 2/3 trial involving more than 500 men with mild-to-moderate pattern hair loss.

In Study 302, the company reported average target-area hair-count increases of 30.3 hairs per square centimetre for once-daily treatment and 33.0 for twice-daily treatment, compared with 7.3 for placebo. Veradermics says Studies 302 and 304 together provide placebo-controlled data from more than 1,000 male participants.

Two registration-directed studies may strengthen the company's regulatory package, but topline press-release results are not a substitute for complete clinical data. Regulators assess the totality of evidence: study design, statistical analyses, safety, manufacturing quality, and proposed labelling.

Veradermics has also been developing VDPHL01 for female pattern hair loss. In an earlier update, the company said enrolment in Study 306, a Phase 2/3 trial in women, had been completed and that topline data were anticipated in the first half of 2027. That is a company-stated timeline, not a guarantee of when results will appear or whether the treatment will prove effective in women.

What approval could mean for the market

If approved for pattern hair loss, VDPHL01 would offer another prescription option for patients seeking treatment beyond topical minoxidil. The company is positioning it as a potential first FDA-approved oral, non-hormonal treatment for pattern hair loss — a more precise description than calling it the first new oral hair-loss drug in 30 years. Oral finasteride has been FDA-approved for male pattern hair loss since 1997, but it works through a different, hormone-related mechanism.

The distinction could matter for patients seeking alternatives to treatments that act on hormone pathways, or who find topical products inconvenient. No medicine is appropriate for everyone, and the benefits, risks, eligibility criteria, and prescribing information for VDPHL01 cannot be determined until the regulatory process is complete.

The company's intellectual-property filings describe patents and applications covering the formulation and method of use, with the earliest stated expiry in 2043. Patent protection can be commercially significant, but it does not establish that a drug will be approved, launched on a particular date, or achieve a specific level of sales.

Veradermics has not set a confirmed commercial launch date. Any estimate that the medicine could reach the market in two or three years should be treated as a projection — dependent on regulatory submissions, FDA review, manufacturing readiness, and the outcome of any additional requirements.

What happens next

The immediate development is that VDPHL01 produced statistically significant improvements in hair counts and patient-reported coverage in a six-month Phase 3 study. Its longer-term prospects will depend on the complete safety and efficacy evidence, regulatory review, and whether the eventual treatment offers a meaningful balance of benefit, tolerability, and convenience for patients.

---